Abstract
Aim: The studies show that dyslipidemia may pose a risk factor for the emergence of malignancies. The study evaluates the lipid parameters of patients diagnosed with hematologic malignancy during diagnosis, investigating their relationship with hematologic malignancy and the parameters' effects on remission and its duration.
Material and Method: The study included 68 male and 63 female patients with a mean age of 66.1±13.9 years. HDL, LDL, TG, and their TC levels diagnosed with hematologic malignancies due to peripheral smear, bone marrow, and lymph node biopsy between 2015 and 2021 were retrospectively analyzed. According to the statistically analyzed association data between cholesterol levels and hematologic malignancies, p<0.05 was considered significant.
Results: Out of all the individuals studied, 12.9% were diagnosed with acute leukemia, 25.1% had chronic leukemia, 32% were diagnosed with multiple myeloma, and 29.7% had lymphoma. Among the patients, 40.5% were in remission, while 59.5% were in relapse clinics. Patients in remission had significantly lower HDL levels compared to those in relapse. However, there was no significant difference between the two groups for LDL, triglycerides, and TC levels.
Conclusion: Some studies show that low HDL levels increase the risk of developing hematologic malignancy, low HDL levels decrease survival in patients with hematologic malignancy, and high HDL levels decrease the risk of recurrence development. Although no correlation was found between hematologic malignancy diagnosis groups and lipid levels, this study shows that HDL levels were higher in relapse clinic patients than in the remission group.
Keywords
References
- Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: insights into pathophysiology and treatments in 2017. Mol Med. 2018; 24(1):11.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405.
- Deshantri AK, Moreira AV, Ecker V, et al. Nanomedicines for the treatment of hematological malignancies. J Control Release. 2018;287:194-215.
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90.
- Tietsche de Moraes Hungria V, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real-world settings: Findings from the hemato-oncology latin america observational registry study. Journal Glob Oncol. 2019; 5:1-19.
- Craver BM, El Alaoui K, Scherber RM, Fleischman AG. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers. 2018; 10(4):104.
- Jeong SM, Choi T, Kim D, et al. Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia. 2021; 35(5):1356-64.
- Kleinstern G, Camp NJ, Berndt SI, et al. Lipid trait variants and the risk of non-hodgkin lymphoma subtypes: A mendelian randomization study. Cancer Epidemiology, Biomarkers Prev. 2020; 29(5):1074-1078.
- Choi J, Peters M, Mueller R. Correlational analysis of ordinal data: From Pearson's r to Bayesian polychoric correlation. Asia Pacific Educ Rev. 2010; 11:459-66.
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249.
- Brendolan A, Russo V. Targeting cholesterol homeostasis in hematopoietic malignancies. Blood. 2022; 139(2):165-76.
- Chimento A, Casaburi I, Avena P, et al. Cholesterol and its metabolites in tumor growth: therapeutic potential of statins in cancer treatment. Front Endocrinol (Lausanne). 2019; 9:807.
- Loosen SH, Kostev K, Luedde M, Luedde T, Roderburg C. Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer. J Cancer Res Clin Oncol. 2022; 148(11):3039-46.
- Wang C, Lin T, Wang X, et al. Low high-density lipoprotein cholesterol levels are associated with malignant intraductal papillary mucinous neoplasms: A multicenter study. Lipids Health Dis. 2021; 20(1):94.
- Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018; 71:54-69.
- Kleinstern G, Camp NJ, Berndt SI, et al. Lipid trait variants and the risk of non-Hodgkin lymphoma subtypes: a Mendelian randomization study. Cancer Epidemiol Biomarkers Prev. 2020; 29(5):1074-8.
- Morimoto Y, Conroy SM, Ollberding NJ, et al. Erythrocyte membrane fatty acid composition, serum lipids, and non-Hodgkin's lymphoma risk in a nested case-control study: the multiethnic cohort. Cancer Causes Control. 2012;23(10):1693-1703.
- Healy FM, Dahal LN, Jones JRE, Floisand Y, Woolley JF. Recent progress in interferon therapy for myeloid malignancies. Front Oncol. 2021; 11:769628.
- Morel S, Leahy J, Fournier M, et al. Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. J Lipid Res. 2017; 58(5):982-93.
- Yavasoglu I, Sargin G, Yilmaz F, et al. Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia. J Natl Med Assoc. 2017;109(1):23-27.
- Choi T, Choi IY, Han K, et al. Lipid level, lipid variability, and risk of multiple myeloma: a nationwide population-based study of 3,527,776 subjects. Cancers. 2021; 13(3):540.
- Gómez-Almaguer D, Marcos-Ramírez ER, Montaño-Figueroa EH, et al. Acute leukemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk. 2017;17(1):46-51.
- Jung W, Jeon KH, Kang J, et al. Association between cholesterol level and the risk of hematologic malignancy according to menopausal status: A Korean nationwide cohort study. Biomedicines. 2022; 10(7):1617.
Abstract
Amaç: Yapılan çalışmalar dislipideminin, malignitelerin ortaya çıkmasında bir risk faktörü olabileceğini göstermektedir. Bu çalışmada hematolojik malignite tanısı alan hastaların tanı anındaki lipid parametreleri değerlendirilerek hematolojik malignite ile ilişkileri ve parametrelerin hastalığın remisyonu ve remisyon süresi üzerine etkileri araştırılmıştır.
Gereç ve Yöntem: Çalışmaya ortalama yaşları 66.1±13.9 yıl olan 68 erkek, 63 kadın hasta dahil edildi. 2015-2021 yılları arasında periferik yayma, kemik iliği ve lenf bezi biyopsi sonucu hematolojik malignite tanısı alan hastaların HDL, LDL, TG ve TK değerleri retrospektif olarak tarandı. Kolesterol seviyeleri ile hematolojik maligniteler arasındaki bağlantı araştırıldı. Veriler istatiksel olarak analiz edildi ve p<0,05 olan değerler anlamlı kabul edildi.
Bulgular: Hastaların %12,9’u akut lösemi, %25,1’i kronik lösemi, %32’si multiple myelom ve %29,7’si lenfoma tanısına sahipti. Hastaların %40,5’i remisyonda iken, %59,5’i de nüks kliniğinde idi. Remisyondaki hastaların HDL değerleri, nüks grubunda bulunan hastalara göre anlamlı ölçüde daha düşüktü. Fakat LDL, TG ve TK değerleri ile remisyon ve nüks grupları arasında anlamlı bir ilişki bulunamadı.
Sonuç: Literatürdeki bazı çalışmalarda düşük HDL seviyesi hematolojik malignite gelişme riskini arttırdığı, aynı zamanda hematolojik maligniteye sahip hastalarda düşük HDL seviyesinin sağ kalımı azalttığı ve yüksek HDL seviyesinin ise nüks gelişme riskini azalttığı gösterilmiştir. Bizim çalışmamızda ise hematolojik malignite tanı grupları ile lipid seviyeleri arasında ilişki saptanmamakla beraber, nüks kliniğindeki hastalarda HDL seviyesinin remisyon grubuna göre daha yüksek olduğu gösterilmiştir.
Keywords
References
- Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: insights into pathophysiology and treatments in 2017. Mol Med. 2018; 24(1):11.
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405.
- Deshantri AK, Moreira AV, Ecker V, et al. Nanomedicines for the treatment of hematological malignancies. J Control Release. 2018;287:194-215.
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90.
- Tietsche de Moraes Hungria V, Chiattone C, Pavlovsky M, et al. Epidemiology of hematologic malignancies in real-world settings: Findings from the hemato-oncology latin america observational registry study. Journal Glob Oncol. 2019; 5:1-19.
- Craver BM, El Alaoui K, Scherber RM, Fleischman AG. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers. 2018; 10(4):104.
- Jeong SM, Choi T, Kim D, et al. Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. Leukemia. 2021; 35(5):1356-64.
- Kleinstern G, Camp NJ, Berndt SI, et al. Lipid trait variants and the risk of non-hodgkin lymphoma subtypes: A mendelian randomization study. Cancer Epidemiology, Biomarkers Prev. 2020; 29(5):1074-1078.
- Choi J, Peters M, Mueller R. Correlational analysis of ordinal data: From Pearson's r to Bayesian polychoric correlation. Asia Pacific Educ Rev. 2010; 11:459-66.
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249.
- Brendolan A, Russo V. Targeting cholesterol homeostasis in hematopoietic malignancies. Blood. 2022; 139(2):165-76.
- Chimento A, Casaburi I, Avena P, et al. Cholesterol and its metabolites in tumor growth: therapeutic potential of statins in cancer treatment. Front Endocrinol (Lausanne). 2019; 9:807.
- Loosen SH, Kostev K, Luedde M, Luedde T, Roderburg C. Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer. J Cancer Res Clin Oncol. 2022; 148(11):3039-46.
- Wang C, Lin T, Wang X, et al. Low high-density lipoprotein cholesterol levels are associated with malignant intraductal papillary mucinous neoplasms: A multicenter study. Lipids Health Dis. 2021; 20(1):94.
- Pirro M, Ricciuti B, Rader DJ, Catapano AL, Sahebkar A, Banach M. High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018; 71:54-69.
- Kleinstern G, Camp NJ, Berndt SI, et al. Lipid trait variants and the risk of non-Hodgkin lymphoma subtypes: a Mendelian randomization study. Cancer Epidemiol Biomarkers Prev. 2020; 29(5):1074-8.
- Morimoto Y, Conroy SM, Ollberding NJ, et al. Erythrocyte membrane fatty acid composition, serum lipids, and non-Hodgkin's lymphoma risk in a nested case-control study: the multiethnic cohort. Cancer Causes Control. 2012;23(10):1693-1703.
- Healy FM, Dahal LN, Jones JRE, Floisand Y, Woolley JF. Recent progress in interferon therapy for myeloid malignancies. Front Oncol. 2021; 11:769628.
- Morel S, Leahy J, Fournier M, et al. Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. J Lipid Res. 2017; 58(5):982-93.
- Yavasoglu I, Sargin G, Yilmaz F, et al. Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia. J Natl Med Assoc. 2017;109(1):23-27.
- Choi T, Choi IY, Han K, et al. Lipid level, lipid variability, and risk of multiple myeloma: a nationwide population-based study of 3,527,776 subjects. Cancers. 2021; 13(3):540.
- Gómez-Almaguer D, Marcos-Ramírez ER, Montaño-Figueroa EH, et al. Acute leukemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk. 2017;17(1):46-51.
- Jung W, Jeon KH, Kang J, et al. Association between cholesterol level and the risk of hematologic malignancy according to menopausal status: A Korean nationwide cohort study. Biomedicines. 2022; 10(7):1617.
Details
| Primary Language | English |
|---|---|
| Subjects | Internal Diseases, Clinical Sciences (Other) |
| Journal Section | Research Article |
| Authors | |
| Publication Date | June 30, 2025 |
| Submission Date | November 19, 2024 |
| Acceptance Date | June 2, 2025 |
| Published in Issue | Year 2025 Volume: 3 Issue: 2 |
